静脉注射用丙种球蛋白对呼吸道合胞病毒治疗的作用

目的:研究静脉注射用丙种球蛋白(IVγG)体内外抗呼吸道合胞病毒(RSV)的作用。方法:①采用微量细胞病变抑制法试验(MCIA),检测不同浓度的IVγG抑制RSV的作用。②建立RSV感染的BALB/c小鼠模型,将40只感染RSV的小鼠分为4组,即IVγG治疗组、病毒唑治疗组、Palivizumab治疗组、生理盐水对照组,及10只未感染RSV的小鼠作为正常对照组,每组10只。于治疗后第5及第7天,分2批处死小鼠,分离病毒并观察肺组织的病理积分。结果:①IVγG具有抑制RSV的作用,其治疗指数(TI)为275,较病毒唑高6倍,较Palivizumab低2倍。②IVγG治疗组小鼠肺组织的病理积分较生理盐水对照组明显减低(P<0.01),但其5d的治疗作用低于Palivizumab治疗组(P<0.05)。结论:IVγG在体内外均有一定的抗RSV的作用,但效果均低于Palivizumab。

Treatment of respiratory syncytial virus by intravenous γ-globulin

AIM: To explore in vitro and in vivo the effect of the intravenous gamma-globulin (IVgammaG) on the respiratory syncytial virus (RSV). METHODS: (1) The microdose cytopathogenic inhibition assay (MCIA) was used to observe the effect of different concentrations of IVgammaG on RSV replication. (2) 40 BALB/c mice were infected with RSV and then randomly divided into four groups: namely, the IVgammaG treatment group, the ribavirin treatment group, the Palivizumab treatment group and the normal saline group (control group). Half of the mice in each group were killed at the fifth day and the seventh day after treatment, respectively, to isolate the virus and perform pathological examination of the lung tissue. RESULTS: (1) IVgammaG inhibited RSV replication in vitro. The treatment index (TI) of IVgammaG was 275, which was about 7 times of TI of ribavirin and one third of Palivizumab. (2) The pathological score of the lung tissue in the IVgammaG group was lower than that of control group (P<0.01), but higher than that of Palivizumab group (P<0.05). CONCLUSION: The IVgammaG has an anti-RSV effect both in vivo and in vitro, but its effect is lower than that of Palivizumab.